|
Oct 9
|
Genmab A/S (GMAB): Among The Stocks With Biggest Upside Potential According to Hedge Funds
|
|
Oct 8
|
GMAB or INCY: Which Is the Better Value Stock Right Now?
|
|
Oct 8
|
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
|
|
Sep 30
|
Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
|
|
Aug 30
|
Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers
|
|
Aug 28
|
Top High Growth Tech Stocks To Watch In August 2024
|
|
Aug 26
|
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 8
|
Genmab Announces Financial Results for the First Half of 2024
|
|
Aug 8
|
Genmab Updates 2024 Financial Guidance
|
|
Aug 5
|
BioNTech exits PD-L1 development with Genmab as Q2 revenues drop
|
|
Aug 5
|
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls
|
|
Aug 5
|
Genmab Takes Full Control of Acasunlimab Development Program
|
|
Jul 29
|
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
|
|
Jul 25
|
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Jun 28
|
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
|
|
Jun 27
|
Completion of Share Buy-back Program
|
|
Jun 27
|
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
|
|
Jun 26
|
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
|
|
Jun 17
|
Transactions in Connection with Share Buy-back Program
|
|
Apr 15
|
Roche reports survival data for new dual-acting lymphoma drug
|